Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

How to Reconstitute Sermorelin: Syringe Selection and Needle Gauge Guide

By
Published Updated Last reviewed
7 linked public sourcesEditorial, sourcing, and corrections policy

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

Key numbers

  • 4.1 cm/yrBaseline mean height velocity in prepubertal children with GH deficiency given sermorelin in the studySource: pubmed.ncbi.nlm.nih.gov, as cited 2026-11-07
  • 8.0 cm/yrMean height velocity at 6 months in prepubertal children with GH deficiency given sermorelin in the studySource: pubmed.ncbi.nlm.nih.gov, as cited 2026-11-07
  • 7.2 cm/yrMean height velocity at 12 months in prepubertal children with GH deficiency given sermorelin in the studySource: pubmed.ncbi.nlm.nih.gov, as cited 2026-11-07

At a glance

  • Approval status / No FDA-approved sermorelin; Geref approvals withdrawn in 2009 [3]
  • What it is / 29-amino-acid GHRH analogue; not growth hormone [5]
  • Published dose, children / 30 mcg/kg subcutaneously once daily at bedtime [1]
  • Published dose, older men / 0.5 mg or 1 mg subcutaneously twice daily for 14 days [2]
  • Sport status / WADA S2.2.4, prohibited at all times [6]

What the published injections looked like

Children. 110 previously untreated prepubertal children with growth hormone deficiency, 86 of them evaluable, received 30 micrograms/kg subcutaneously once daily at bedtime for up to a year. Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months [1].

Older men. 10 healthy men with a mean age of 68 took 0.5 mg and 1 mg subcutaneously twice daily for 14 days each, compared with 9 young men. At the higher dose, 24-hour growth hormone and IGF-I rose to levels not significantly different from the young men [2].

Both were study regimens, not recommended doses; the children's regimen was weight-based [1][2].

The dilution arithmetic

Two numbers set the volume you draw: the amount of peptide in the vial and the volume of liquid added.

  • Concentration (mcg/mL) = peptide mass in the vial (mcg) divided by diluent volume added (mL)
  • Draw volume (mL) = dose (mcg) divided by concentration (mcg/mL)

Purely as arithmetic: a vial labeled 3 mg (3,000 mcg) with 2 mL of diluent added would give 1,500 mcg/mL, and a 300 mcg dose would be 0.2 mL. That illustrates the calculation, not a sermorelin dose.

Questions worth asking

Choose the questions you want to keep

Jay Patel on how to mix Sermorelin for insulin syringe dosing

Jay Patel argues that Sermorelin should be mixed to a concentration that makes the dose easy to measure in an insulin syringe. He describes reconstituting three milligrams of the peptide with one and a half milliliters of bacteriostatic water, which he says gives roughly two hundred micrograms per ten units. He stresses refrigerated storage and sterile technique, and he says the mixed solution stays usable for up to thirty days. In his view, the mixing step matters as much as the protocol itself, and he tells viewers to follow up with their medical provider.

Who is speaking?

Jwalant Patel PA-C. Physician assistant (PA-C), as described on the channel Background

Episode notes and full video

Compounded status

Sermorelin sold in the United States today is compounded, and compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [4].

Frequently asked questions

What determines the volume I draw?
The dose and the concentration. Divide the dose in micrograms by the concentration in mcg/mL: at 1,500 mcg/mL, 300 mcg is 0.2 mL. That is an arithmetic example only.
How much diluent goes into a sermorelin vial?
The published study abstracts do not state a diluent volume [1][2]. The diluent volume together with the peptide mass in the vial sets the concentration: mass divided by millilitres added.
What doses were used in the published studies?
30 micrograms/kg subcutaneously once daily at bedtime in children [1]; 0.5 mg or 1 mg subcutaneously twice daily for 14 days in older men [2]. These were study regimens, not recommended doses.
Is sermorelin FDA-approved?
No. Geref was discontinued in 2008 and FDA withdrew its approvals effective June 18, 2009 [3]. Sermorelin sold in the United States today is compounded, and compounded drugs are not FDA-approved [4].

What people actually ask

What size needle for peptide injection?

No needle gauge or length for sermorelin is stated. The published study abstracts give a dose and a subcutaneous route but do not name a syringe type, needle gauge, needle length or diluent volume. The volume you draw, dose divided by concentration, is what determines which syringe size is practical.

How much sermorelin should I inject?

No dose to use is given. The published regimens were study regimens, not recommended doses: children received 30 micrograms/kg subcutaneously once daily at bedtime, and older men received 0.5 mg or 1 mg subcutaneously twice daily for 14 days. The children's regimen was weight-based.

How to reconstitute a 10 mg vial of sermorelin?

No reconstitution volume for a 10 mg vial is given. The published study abstracts do not state a diluent volume. The concentration is the peptide mass in the vial divided by the millilitres of diluent added, and the draw volume is the dose divided by that concentration.

References

  1. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group
  2. Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men
  3. Federal Register. Determination That Geref (sermorelin acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. 2013. Determination that Geref (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness
  4. Federal Register public inspection document 2026-22192. 2026. Federal Register public inspection document 2026-22192
  5. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
  6. World Anti-Doping Agency. 2026 Prohibited List. 2025. WADA 2026 Prohibited List
  7. MyFitMed | Jwalant Patel PA-C. STOP Injecting Sermorelin WRONG! (Dosage, Timing, Mixing, & Protocols You Need to Know). Accessed 2026-11-11.
Evidence overview for How to Reconstitute Sermorelin: Syringe Selection and Needle Gauge Guide